药物使用与显微镜性结肠炎风险:美国50岁以上成人的倾向匹配分析(2014-2024)
该回顾性队列研究基于TriNetX数据库(2014-2024),纳入≥50岁无既往显微镜性结肠炎或炎症性肠病的成人,比较NSAIDs、PPIs、SSRIs、ACEIs、ARBs、他汀类使用者与倾向匹配未治疗对照的显微镜性结肠炎发生风险。结果显示NSAIDs、PPIs和SSRIs与风险增加相关,而ACEIs、ARBs和他汀类无显著关联。
要点
- NSAIDs、PPIs和SSRIs与显微镜性结肠炎风险增加相关。
- ACEIs、ARBs和他汀类未显示与显微镜性结肠炎风险相关。
- 对新发慢性腹泻患者应考虑进行药物回顾。
核心结论
- NSAIDs、PPIs和SSRIs与显微镜性结肠炎风险增加相关,ACEIs、ARBs和他汀类无显著关联。
研究设计与样本
- 基于TriNetX数据库(2014-2024)的回顾性队列研究,纳入≥50岁、至少一次医疗接触且无既往显微镜性结肠炎或炎症性肠病的成人。
- 暴露定义为某药物类别≥3次处方,各治疗组与未治疗对照按年龄、性别、种族、合并症和既往结肠镜检查进行1:1倾向评分匹配。
- 主要结局为通过新诊断代码识别的 incident 显微镜性结肠炎,采用Cox比例风险模型估计风险比(HR)和95%置信区间(CI)。
主要发现
- 倾向评分匹配后,队列包括907,266名NSAIDs使用者、750,009名PPIs使用者、308,310名SSRIs使用者、393,952名ACEIs使用者、298,480名ARBs使用者和548,339名他汀类使用者。
- 2年内,显微镜性结肠炎风险增加与NSAIDs相关(HR 1.15;95% CI 1.02-1.30)。
- 显微镜性结肠炎风险增加与PPIs相关(HR 1.36;95% CI 1.19-1.54)。
- 显微镜性结肠炎风险增加与SSRIs相关(HR 1.52;95% CI 1.27-1.83)。
- ACEIs、ARBs和他汀类与显微镜性结肠炎无显著关联。
关键数值与推荐
- 暴露定义:某药物类别≥3次处方。
- 主要结局:通过新诊断代码识别的 incident 显微镜性结肠炎。
临床怎么用
- 对新发慢性腹泻患者,应考虑回顾NSAIDs、PPIs和SSRIs等药物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between medications-including non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs)-and microscopic colitis (MC) remains controversial. While earlier studies suggested increased risk, more recent analyses have challenged these findings, citing methodological limitations. We evaluated the risk of MC among commonly implicated medications using a large national U.S. METHODS: Using the TriNetX database (2014-2024), we conducted a retrospective cohort study including adults ≥ 50 years with at least one documented healthcare encounter and no prior MC or inflammatory bowel disease. Exposure was defined as ≥ 3 prescriptions within a drug class. Treatment groups (NSAIDs, PPIs, SSRIs, ACE inhibitors [ACEIs], angiotensin receptor blockers [ARBs], statins) were 1:1 propensity score-matched (PSM) to untreated controls on age, sex, race, comorbidities and previous colonoscopy. The primary outcome was incident MC, identified by new diagnostic codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: After PSM, cohorts included 907,266 NSAID, 750,009 PPI, 308,310 SSRI, 393,952 ACEI, 298,480 ARB users and 548,339 statin users. Over 2 years, MC risk was increased with NSAIDs (HR 1.15; 95% CI, 1.02-1.30), PPIs (HR 1.36; 95% CI, 1.19-1.54) and SSRIs (HR 1.52; 95% CI, 1.27-1.83). ACEIs, ARBs and statins were not associated with MC. CONCLUSIONS: In this large cohort, NSAIDs, PPIs and SSRIs were associated with an increased risk of MC, whereas no significant association was observed for ACEIs, ARBs or statins. Medication review should be considered in patients with new-onset chronic diarrhoea.
引用
- Kilani Y, Heis F, Dugaesescu A, et al. Medication Use and Risk of Microscopic Colitis: A Propensity-Matched Analysis of US Adults ≥ 50 Years (2014-2024). Aliment Pharmacol Ther. 2026. PMID: 42765157. doi:10.1111/apt.70985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。